Somalogic Partners with NEC in Effort to More Broadly Leverage Aptamer-Based Technology
September 10, 2010
Somalogic Partners with NEC in Effort to More Broadly Leverage Aptamer-Based Technology
The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - NYU, Somalogic Present Data on Protein Biomarker Test for Mesothelioma
April 8, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - TGen's Center for Proteomics Named a Waters Center of Innovation
August 26, 2011 / ProteoMonitor - Some Proteomics Firms Exploring Next-Generation Sequencing for Biomarker Research
May 6, 2011 / ProteoMonitor